Vir Biotechnology, Inc.
NASDAQ:VIRBiotechnology
-$0.25 today
- Market cap
- $1.52B
- Beta
- 1.64
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.00
Volume 1.89M
Average 1.76M
Returns on capital
Vir Biotechnology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.2%
avg 0.4%
ROIC
-50.9%
avg -29.7%
ROA
-43.7%
avg -24.7%
Analysis
ROA is currently the strongest return metric at -43.7% versus its period average of -24.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Marianne De Backer | President, CEO & Director | USD 2.03M | 57 | 286.65K | 0.17% |
Jeff Calcagno | Executive Vice President & Chief Business Officer | USD 860.49K | 65 | — | — |
Vanina De Verneuil | Executive Vice President, General Counsel & Corporate Secretary | USD 844.34K | 47 | 110.19K | 0.07% |
Lawrence Corey | Co-Founder & Scientific Advisor | USD 177.66K | 79 | — | — |
Louis J. Picker | Co-Founder & Scientific Advisor | USD 177.66K | — | — | — |
Jennifer Eileen Towne | Executive Vice President & Chief Scientific Officer | — | — | — | — |
Kiki Patel | Head of Investor Relations | — | — | — | — |
Maninder Hora | Executive Vice President & Chief Technical Operations Officer | — | 72 | — | — |
Aziz Sawaf | Executive VP, CFO & Principal Financial Officer | — | 44 | 0 | <0.01% |
Brent Sabatini | Senior Vice President, Principal Accounting Officer & Chief Accounting Officer | — | 52 | 61.90K | 0.04% |
Toby Medaris | Executive Vice President & Chief Human Resources Officer | — | — | — | — |
Carolyn Wang | Senior Vice President of Corporate Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 3, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
33
$8.15M
Net Transaction Value
−$8.15M
Net selling
Most Active
SATO VICKI L
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 3, 26Nov 3, 2026 | de Verneuil Vanina Direct | Sell | $26.7K$26,717.70 |
| Nov 2, 26Nov 2, 2026 | de Verneuil Vanina Direct | Sell | $15.2K$15,221.56 |
| Jun 1, 26Jun 1, 2026 | Napolitano Janet Direct | Sell | $30.2K$30,240.00 |
| Jun 1, 26Jun 1, 2026 | Sabatini Brent Direct | Sell | $3.6K$3,581.55 |
| May 1, 26May 1, 2026 | SATO VICKI L Direct | Sell | $221K$221,025.20 |
| Apr 6, 26Apr 6, 2026 | De Backer Marianne Direct | Sell | $664.4K$664,350.20 |
| Apr 1, 26Apr 1, 2026 | SATO VICKI L Direct | Sell | $199.6K$199,617.00 |
| Mar 23, 26Mar 23, 2026 | Sabatini Brent Direct | Sell | $70.3K$70,324.32 |
| Mar 2, 26Mar 2, 2026 | SATO VICKI L Direct | Sell | $207.2K$207,185.02 |
| Mar 2, 26Mar 2, 2026 | SATO VICKI L Direct | Sell | $2K$1,996.00 |
1–10 of 33
Summary
Insiders reported 0 buys worth $0.00 and 33 sells worth $8.15M over the last 12 months. That adds up to net selling of $8.15M. SATO VICKI L was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -65.1% | +36.8% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -65.1% over three years. Forward estimates point to Revenue at +36.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Vir Biotechnology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about VIR's management, answered from reported figures.
Who manages VIR?
Vir Biotechnology, Inc. (VIR) lists 12 active executives. The top listed executive is Jeff Calcagno, Executive Vice President & Chief Business Officer.
Are VIR insiders buying or selling?
Recent insider activity shows net buying of $1.39M.
Continue the stock analysis
Jump to another research area for this company.